Page last updated: 2024-11-06

tebuquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Tebuquine is a synthetic antimalarial drug that was initially developed in the 1960s. It acts by inhibiting the growth of the parasite Plasmodium falciparum, the most deadly species responsible for malaria. Tebuquine is a quinoline derivative and exhibits activity against chloroquine-resistant strains of the parasite. The drug has shown promising results in clinical trials for the treatment of uncomplicated malaria. Tebuquine's unique mechanism of action and its efficacy against chloroquine-resistant malaria make it an important drug for research and development of new antimalarial therapies. Further research is ongoing to optimize its pharmacokinetic properties and to develop new formulations for improved efficacy and patient compliance.'

Cross-References

ID SourceID
PubMed CID71991
CHEMBL ID339049
SCHEMBL ID538503
MeSH IDM0130286

Synonyms (31)

Synonym
NCI60_003357
74129-03-6
D06018
tebuquine (usan/inn)
tebuquine
CHEMBL339049
wr-228,258
ci-897
wr-228258
2-[(tert-butylamino)methyl]-6-(4-chlorophenyl)-4-[(7-chloroquinolin-4-yl)amino]phenol
3-((tert-butylamino)methyl)-4'-chloro-5-((7-chloro-4-quinolyl)amino)-2-biphenylol
tebuquina
(1,1'-biphenyl)-2-ol, 4'-chloro-5-((7-chloro-4-quinolinyl)amino)-3-(((1,1-dimethylethyl)amino)methyl)-
699q1xt4en ,
wr 228,258
tebuquine [usan:inn]
unii-699q1xt4en
ci 897
tebuquina [spanish]
tebuquinum
tebuquinum [latin]
SCHEMBL538503
tebuquine [inn]
tebuquine [usan]
DTXSID50225084
teboquine
4-methoxypyridine-2-carboxylicacidhydrazide
SB18677
Q27264335
gtpl10392
AKOS040749625

Research Excerpts

Overview

Tebuquine is a 4-aminoquinoline that shows significantly more potency as an antimalarial than amodiaquine and chloroquine both in vitro and in vivo.

ExcerptReferenceRelevance
"Tebuquine (5) is a 4-aminoquinoline that is significantly more active than amodiaquine (2) and chloroquine (1) both in vitro and in vivo. "( Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
Bray, PG; Hawley, SR; O'Neill, PM; Park, BK; Storr, RC; Ward, SA; Willock, DJ, 1997
)
1.98
"Tebuquine is a 4-aminoquinoline that shows significantly more potency as an antimalarial than amodiaquine and chloroquine both in vitro and in vivo. "( Exploration of rate-limiting conformational state for 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl][1,1'-biphenyl]-2-ols and N(omega)-oxides (tebuquine analogues) for antimalarial activity using molecular shape analysis and molecular field analy
Chhabra, S; Ghoshal, N; Rai, N; Sharma, P,
)
1.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID140550Antimalarial activity tested against trophozoite induced Plasmodium berghei in mice (Mus musculus) expressed as change in mean survival time after a single dose of 320 mg/kg (subcutaneously)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID129940Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 20 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129945Change in mean survival time for control (average of 6.2 days) versus treated mice (Mus musculus) 72 hrs after 80 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129943Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 5 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID277795Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and antimalarial activity of new isotebuquine analogues.
AID135293Antimalarial activity as 60-day survivors in infected mice (Mus musculus) after single 320mg/kg subcutaneous dose 72 hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129938Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 160 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID277797Toxicity against murine J774 macrophage cells2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and antimalarial activity of new isotebuquine analogues.
AID129433Number of mice surviving at 60 days postinfection when administered as a single dose of 320 mg/kg (sc) 72-h post infection (delta MST)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID135295Antimalarial activity of compound administered as a single subcutaneous dose of 5mg/kg, 72-h postinfection measured as number of mice (Mus musculus) surviving at 60 days postinfection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129430Number of mice surviving at 60 days postinfection when administered as a single dose of 160 mg/kg (sc) 72-h post infection (delta MST)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID129936Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 1.25 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID158706In vitro inhibition of chloroquine-resistant Plasmodium falciparum K11997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
AID135291Antimalarial activity as 60-day survivors in Plasmodium berghei infected mice (Mus musculus) after single 160mg/kg subcutaneous dose 72 hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129434Number of mice surviving at 60 days postinfection when administered as a single dose of 40 mg/kg (sc) 72-h post infection (delta MST)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID129438Number of mice surviving at 60 days postinfection when administered as a single dose of 80 mg/kg (sc) 72-h post infection (delta MST)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID135292Antimalarial activity as 60-day survivors in infected mice (Mus musculus) after single 20 mg/kg subcutaneous dose 72hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID277794Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and antimalarial activity of new isotebuquine analogues.
AID129431Number of mice surviving at 60 days postinfection when administered as a single dose of 20 mg/kg (sc) 72-h post infection (delta MST)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID135290Antimalarial activity of compound administered as a single subcutaneous dose of 10mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID277796Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM91C2352007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and antimalarial activity of new isotebuquine analogues.
AID129937Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 10 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID396379Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by [G-3H]hypoxanthine uptake2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway.
AID129941Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 320 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID158707In vitro inhibition of chloroquine-sensitive Plasmodium falciparum HB31997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
AID135297Antimalarial activity, administered as a single subcutaneous dose of 80 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129939Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 2.5 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID228277Cellular accumulation ratio (CAR) for chloroquine sensitive HB3 strain of Plasmodium falciparum1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
AID140552Antimalarial activity tested against trophozoite induced Plasmodium berghei in mice (Mus musculus) expressed as change in mean survival time after a single dose of 640 mg/kg (subcutaneously)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID129944Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 640 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID140551Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 40 mg/kg subcutaneous dose1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID129942Difference in mean survival time in mice (Mus musculus) (control = 6.2 days) after single 40mg/kg subcutaneous dose 72hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID140549Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 20 mg/kg subcutaneous dose1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID140548Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 160 mg/kg subcutaneous dose1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
AID135294Antimalarial activity, administered as a single subcutaneous dose of 40 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID140553Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 80 mg/kg subcutaneous dose1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antimalarial effects of 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl] -6-alkylphenols and their N omega-oxides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's2 (15.38)18.2507
2000's3 (23.08)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.45 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]